Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Nervenarzt ; 88(3): 222-233, 2017 Mar.
Article in German | MEDLINE | ID: mdl-27220643

ABSTRACT

In this article the guideline-adherent psychiatric psychotherapeutic treatment of patients with bipolar disorders is outlined and the required resources are estimated. Based on the core recommendations of the S3 guidelines for diagnostics and treatment of bipolar disorders published in 2012, inpatient treatment needs in hours per week and per patient are determined for both manic and bipolar depressive episodes. The resulting staffing requirements are estimated on this basis. In summary, for guideline-adherent inpatient psychiatric psychotherapeutic treatment the additional needs regarding the physician/psychotherapeutic domain add up to 44 min per patient and week during a manic episode and 88 min for patients with bipolar depression when compared to current psychiatry staffing regulations.


Subject(s)
Bipolar Disorder/therapy , Hospitalization/statistics & numerical data , Personnel Staffing and Scheduling/statistics & numerical data , Practice Guidelines as Topic , Psychotherapy/standards , Workload/statistics & numerical data , Bipolar Disorder/diagnosis , Bipolar Disorder/epidemiology , Germany/epidemiology , Guideline Adherence/standards , Guideline Adherence/statistics & numerical data , Humans , Inpatients/statistics & numerical data , Needs Assessment , Personnel Staffing and Scheduling/standards , Psychiatry/standards , Psychiatry/statistics & numerical data , Workload/standards
2.
Nervenarzt ; 86(9): 1157-61, 2015 Sep.
Article in German | MEDLINE | ID: mdl-26341836

ABSTRACT

Lithium salts are the recommended first-line treatment (gold standard) in national and international treatment guidelines for acute and maintenance treatment of affective disorders, such as bipolar disorders. Lithium has also been shown to have a unique protective effect against suicide in patients suffering from affective disorders. Despite the well-known acute and long-term adverse effects lithium therapy can be safely administered if patients are properly educated and carefully monitored. A recent study from France now shows that patients with severely impaired renal function who had been treated with lithium salts for more than 10 years could have an increased risk for kidney tumors (benign and malignant). This resulted in an adjustment concerning information within the package leaflet by European authorities. The authors of this article reflect the currently available data in order to better understand and handle this new finding and to warn about uncritical reactions including withdrawal of lithium in successfully treated patients. This article provides clinical recommendations to provide further insight relating to the risk of kidney cancer in long-term lithium therapy.


Subject(s)
Bipolar Disorder/drug therapy , Bipolar Disorder/epidemiology , Kidney Neoplasms/epidemiology , Kidney Neoplasms/prevention & control , Lithium Compounds/adverse effects , Lithium Compounds/therapeutic use , Comorbidity , Europe/epidemiology , Evidence-Based Medicine , Humans , Kidney Neoplasms/etiology , Risk Factors , Treatment Outcome
3.
BMC Psychiatry ; 15: 117, 2015 May 19.
Article in English | MEDLINE | ID: mdl-25986590

ABSTRACT

BACKGROUND: Lithium has proven suicide preventing effects in the long-term treatment of patients with affective disorders. Clinical evidence from case reports indicate that this effect may occur early on at the beginning of lithium treatment. The impact of lithium treatment on acute suicidal thoughts and/or behavior has not been systematically studied in a controlled trial. The primary objective of this confirmatory study is to determine the association between lithium therapy and acute suicidal ideation and/or suicidal behavior in inpatients with a major depressive episode (MDE, unipolar and bipolar disorder according to DSM IV criteria). The specific aim is to test the hypothesis that lithium plus treatment as usual (TAU), compared to placebo plus TAU, results in a significantly greater decrease in suicidal ideation and/or behavior over 5 weeks in inpatients with MDE. METHODS/DESIGN: We initiated a randomized, placebo-controlled multicenter trial. Patients with the diagnosis of a moderate to severe depressive episode and suicidal thoughts and/or suicidal behavior measured with the Sheehan-Suicidality-Tracking Scale (S-STS) will be randomly allocated to add lithium or placebo to their treatment as usual. Change in the clinician administered S-STS from the initial to the final visit will be the primary outcome. DISCUSSION: There is an urgent need to identify treatments that will acutely decrease suicidal ideation and/or suicidal behavior. The results of this study will demonstrate whether lithium reduces suicidal ideation and behavior within the first 5 weeks of treatment. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02039479.


Subject(s)
Depressive Disorder, Major/drug therapy , Depressive Disorder, Major/psychology , Lithium/pharmacology , Lithium/therapeutic use , Suicidal Ideation , Suicide Prevention , Suicide/psychology , Adult , Clinical Protocols , Female , Humans , Male , Middle Aged , Treatment Outcome
4.
Eur Psychiatry ; 30(1): 99-105, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25498240

ABSTRACT

PURPOSE: Two common approaches to identify subgroups of patients with bipolar disorder are clustering methodology (mixture analysis) based on the age of onset, and a birth cohort analysis. This study investigates if a birth cohort effect will influence the results of clustering on the age of onset, using a large, international database. METHODS: The database includes 4037 patients with a diagnosis of bipolar I disorder, previously collected at 36 collection sites in 23 countries. Generalized estimating equations (GEE) were used to adjust the data for country median age, and in some models, birth cohort. Model-based clustering (mixture analysis) was then performed on the age of onset data using the residuals. Clinical variables in subgroups were compared. RESULTS: There was a strong birth cohort effect. Without adjusting for the birth cohort, three subgroups were found by clustering. After adjusting for the birth cohort or when considering only those born after 1959, two subgroups were found. With results of either two or three subgroups, the youngest subgroup was more likely to have a family history of mood disorders and a first episode with depressed polarity. However, without adjusting for birth cohort (three subgroups), family history and polarity of the first episode could not be distinguished between the middle and oldest subgroups. CONCLUSION: These results using international data confirm prior findings using single country data, that there are subgroups of bipolar I disorder based on the age of onset, and that there is a birth cohort effect. Including the birth cohort adjustment altered the number and characteristics of subgroups detected when clustering by age of onset. Further investigation is needed to determine if combining both approaches will identify subgroups that are more useful for research.


Subject(s)
Age of Onset , Bipolar Disorder/diagnosis , Adult , Aged , Cluster Analysis , Cohort Studies , Databases, Factual , Female , Global Health , Humans , International Cooperation , Male , Middle Aged , Mood Disorders/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL
...